מכפיל EV/EBITDA: Puma Biotechnology Inc (PBYI)

The share price retrospective for Puma Biotechnology (PBYI) demonstrates an EV/EBITDA multiple of 7.95. The business relies on the sale of Nerlynx, where patent protection guarantees a stable cash flow and high margins. Puma Biotechnology (PBYI) operates within a secure legal framework that precludes trade sanctions. High confidence within the medical community regarding the brand's targeted developments ensures the success of innovative treatment methods for specific forms of oncology.

Puma Biotechnology's high authority in breast cancer therapy ensures stable demand for its developments. The company's current EV/EBITDA value of 7.95 reflects the ratio of total enterprise value to operating profit before taxes and amortization. This metric allows for an assessment of the asset's real value accounting for debt load while excluding the influence of tax policy. Such an approach confirms the resilience of the issuer's financial model.